Pharming Group to participate in September investor conferences
September 04, 2024 01:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group reports second quarter and first half 2024 financial results and provides business update
August 01, 2024 01:00 ET
|
Pharming Group N.V.
Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue...
Pharming Group to report second quarter and first half 2024 financial results on August 1
July 18, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024...
Pharming Group to participate in June investor conferences
June 03, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
May 30, 2024 16:44 ET
|
Pharming Group N.V.
Leiden, the Netherlands, May 30, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing...
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
May 21, 2024 11:30 ET
|
Pharming Group N.V.
Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today,...
Pharming Group to participate in May investor conference
May 20, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
May 15, 2024 01:00 ET
|
Pharming Group N.V.
THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE...
Pharming Group reports first quarter 2024 financial results and provides business update
May 08, 2024 01:00 ET
|
Pharming Group N.V.
First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST®RUCONEST® revenues...
Pharming Group to report first quarter 2024 financial results on May 8
April 24, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial...